Measurement of changes in antihypertensive drug utilisation following primary care educational interventions

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 3, 2007, Pages 297-308

  Horn, Fiona E ^a   Mandryk, John A ^a   Mackson, Judith M ^a   Wutzke, Sonia E ^a   Weekes, Lynn M ^a   Hyndman, Rob J ^b  

^a National Prescribing Service   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Antihypertensives; Decay; Educational interventions; Primary care; Regression methods; Time series analysis

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ARTICLE; AUSTRALIA; DRUG CHOICE; DRUG MARKETING; DRUG UTILIZATION; GENERAL PRACTICE; HEALTH EDUCATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MEDICAL AUDIT; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLICATION; TIME SERIES ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; DRUG UTILIZATION; EDUCATION, MEDICAL, CONTINUING; HUMANS; HYPERTENSION; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; REGRESSION ANALYSIS; SOCIAL MARKETING; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 33947240362     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1243     Document Type: Article

References (25)

1. Weekes LM, Mackson JM, Fitzgerald M, et al. National Prescribing Service: creating an implementation arm for national medicines policy. Br J Clin Pharmacol 2005; 59: 112-116.
2. Grol R, Grimshaw J. From best evidence of best practice: effective implementation of change in patients'care. The Lancet 2003; 362: 1225-1230.
3. Anonymous. 1999 Guide to Management of Hypertension for Doctors. National Heart Foundation of Australia; 1999, 1-15.
4. World Health Organisation Group ISoHW. J Hypertens 1999; 151-183.
5. Steven ID, Wing L. Control and cardiovascular risk factors of hypertension: an assessment of a sample of patients. Aust Fam Physician 1999; 28: 45-48.
6. Britt H, Miller GC, Charles J, et al.. BEACH survey: SAND abstract No.26. Prevalence of diagnosed hypertension and difficulties in treatment http://www.fmrc.org.au/Beach/ Abstracts/26-Hypertension.pdf. Accessed 16-08-05
7. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999; 282: 786-790.
8. Wright JM, Lee CH, Chambers GK. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug? Can Med Assoc J 1999; 161(1): 25-32.
9. Robertson J, Fryer JL, O'Connell DL, Smith AJ, Henry D. Limitations of Health Insurance Commission (HIC) data for deriving prescribing indicators. Med J Australia 2002; 176: 419-424.
10. Donnelly N, McManus P, Dudley J, Hall W. Impact of increasing the re-supply interval on the seasonality of subsidised prescription use in Australia. Aust NZ J Public Health 2000; 24(6): 603-606.
11. Cleveland RB, Cleveland WS, McRae JE, Terpenning I. STL: a seasonal-trend decomposition procedure based on Loess (with discussion). J Off Star 1990; 6: 3-73.
12. Makridakis S, Wheelwright S, Hyndman RJ. Forecasting: Methods and applications. John Wiley & Sons: New York, 1998.
13. Edmonds DJ, Dumbrell DM, Primrose JG, McManus P, Birkett DJ, Demirian V. Development of an Australian drug utilization database: a report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Pharmaco Economics 1993; 3(6): 427-432.
14. Robertson J, Henry D, Dobbins T, Sprogis A, Terry R, Ireland M. Prescribing patterns in general practice - a comparison of two data sources. Aust Fam Physician 1999; 28(11): 1186-1190.
15. Kerr SJ, Mant A, Horn FE, et al. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust 2003; 179: 403-407.
16. McManus P, Mant A, Mitchell PB, etal. Recent trends in the use of antidepressant drugs in Australia, 1990-1998. Med J Aust 2000; 173: 458-461.
17. Ray WA, Schaffner W, Federspiel CF. Persistence of improvement in antibiotic prescribing in office practice. JAMA 1985 Mar 22-29; 253(12): 1774-1776.
18. Raisch DW, Bootman JL, Larson LN, McGhan WF. Improving antiulcer agent prescribing in a health maintenance organization. Am J Hosp Pharm 1990 Aug; 47(8): 1766-1773.
19. Majumdar SR, McAlister FA, Sournerai SB. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. Am J Med 2003; 115: 467-472.
20. The ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: (The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.). JAMA 2002; 288: 2981-2997.
21. Wing LM, Reid CM, Ryan P, et al. Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Clin Exp Hypertens 1997 Jul-Aug 19(5-6): 779-791.
22. World Health Organisation, International Society of Hypertension Writing Group. J Hypertens 2003; 21: 1983-1992.
23. Guide to the Management of Hypertension for Doctors. National Heart Foundation of Australia 2003. Canberra.
24. Commonwealth of Australia Department of Health and Ageing. General Practice in Australia 2000. Canberra.
25. Grimshaw JM, Thomas RE, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004; 8: 1-72.